Search alternatives:
mg decrease » _ decrease (Expand Search), nn decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
10 mg » 10 mm (Expand Search)
mg decrease » _ decrease (Expand Search), nn decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
10 mg » 10 mm (Expand Search)
-
641
Tau phosphorylation is decreased in neurons treated with 20 mM KCl.
Published 2017“…The phosphorylation of S199/S202, T181, T205 and S404 was not significantly affected by 10mM of KCl treatment whereas the phosphorylation of all these sites was decreased by 20mM of KCl treatment. The signal of the phospho-antibodies was normalized to that of total Tau (n = 5, mean ± SEM, unpaired t-test two-tailed, *<i>P</i> < 0.05, ***<i>P</i> < 0.001). …”
-
642
The numbers of mature T cells from transgenic mice bearing mutated CD3ε were decreased, and they were actively proliferating in a homeostatic manner.
Published 2009“…Fold decreases for the two populations are indicated. Data shown are for 8 tgε<sup>Mut</sup> mice and 13 wt control mice (4 BL6, 1 tgε<sup>WT</sup>cd3ε<sup>+/−</sup>, 5 tgε<sup>Mut</sup>cd3ε<sup>+/−</sup>, and 3 tgε<sup>WT</sup>). …”
-
643
-
644
-
645
-
646
Structure of YOLOv5s-SBC.
Published 2024“…Compared to the original model, P-YOLOv5s-GRNF decreased parameters by 18%, decreased model size to 11.9MB, decreased FLOPs to 14.5G, and increased FPS by 4.3. …”
-
647
Phenethyl isothiocyanate activates leptin signaling and decreases food intake
Published 2018“…Leptin is a weight-reducing hormone produced by adipose tissue, which decreases food intake <i>via</i> hypothalamic leptin receptors (Ob-Rb) and the Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) signaling pathway. …”
-
648
-
649
-
650
A summary of the included study characteristics.
Published 2025“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
-
651
-
652
-
653
Decrease in ΔΨ on transition from the oxidized to the reduced state.
Published 2011“…<p>(A) Predicted dynamics of the transition induced by addition of 2 mM succinate to mitochondria initially in the oxidized state in the presence of 5 mM pyruvate, under the conditions of various proton leaks through the inner menbrane, slow leak, k<sub>lk</sub> = 17000, and fast leak, k<sub>lk</sub> = 80000 mL/(s·mg prot) (eq.H.1). …”
-
654
-
655
FTY720 decreased viability, proliferation, and motility and induced apoptosis in human hepatoblastoma cells.
Published 2019“…(B) Following 24 hours of treatment with FTY720, the proliferation of HuH6 cells measured using the CellTiter 96 cell proliferation assay was significantly decreased (IC<sub>50</sub> = 6.4 μM, p ≤ 0.05). (C) HuH6 cells were plated and allowed to reach 80% confluence, at which time the media was changed for fresh media (0, 5, or 8 μM FTY720) and a standard scratch wound was made. …”
-
656
Dose-dependent increase in NREM sleep and decrease in wakefulness by <i>p</i>.<i>o</i>. administration of TEG in mice.
Published 2017“…All administrations were done at the onset of dark period (17:00 h). Data presented as mean ± SEM; n = 6; *p≤0.05, **p≤0.01 vs vehicle by using paired t-test for time course data (C, D and E), and one-way ANOVA followed by least square difference (LSD) post-hoc test for dose-response data (F and G). # #p≤0.01 vs TEG (10 mg/head).…”
-
657
-
658
-
659
Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF- D Levels Decrease
Published 2011“…Kidney angiomyolipomas regrew when sirolimus was discontinued but responses tended to persist if treatment was continued after week 52. We observed regression of brain tumors (SEGAs) in 7/11 cases (26% mean decrease in diameter), regression of liver angiomyolipomas in 4/5 cases (32.1% mean decrease in longest diameter), subjective improvement in facial angiofibromas in 57%, and stable lung function in women with TSC/LAM (n = 15). …”
-
660